



September 24, 2024 – Prague, Czech Republic & Hamburg, Germany

PHARMNET Acquires MONIPOL Biotech GmbH and Expands European Footprint

PHARMNET, a full-service CRO with headquarters in Prague, Czech Republic, announced the acquisition of MONIPOL Biotech GmbH in Hamburg, Germany and set up of MONIPOL Biotech PL Sp. z o.o. in Kraków, Poland. PHARMNET, which has long-established capability in running trials across all of Europe, will now have its own in-country operations in the Czech Republic, Poland, Germany, Slovakia and Hungary.

The acquisition will benefit clients through providing wider coverage, local-language monitoring resource and a broader scope of services from the combined MONIPOL / PHARMNET team. The MONIPOL offices will maintain their branding and be part of the PHARMNET Group.

PHARMNET's CEO, Jan Maláč, said, "We are thrilled to be working with the MONIPOL team. The acquisition will bring greater flexibility for our combined client base including an excellent site network covering the whole of Central Europe, strong regulatory expertise in both drug and medical device studies, and a robust quality system. It bolsters our hallmarks of rapid patient recruitment, excellent project management, tailored solutions with a high degree of flexibility, and of course top-quality data. Given our office locations and streamlined processes, we are enabled to be cost competitive so the overall package is reliability and value for our clients."

About MONIPOL

The MONIPOL group of companies have 25 years of experience in monitoring and organizing multicenter clinical trials for biotechnology, small/midsize pharma and medical device companies, covering Phase I-IV clinical trials in a wide range of therapeutic areas, with a particular focus on early-phase studies. They have completed 167 studies and have a strong focus on quality and regulatory compliance.

About PHARMNET

PHARMNET is a Clinical Research Organization based in the Czech Republic and founded in 1994. Since then, the company has successfully completed more than 450 projects (Phase I to IV) in drug and medical device development. At its core, the company prides itself on adaptability and recognizes the importance of tailoring its approach to suit unique clinical research requirements.

Contacts



Silvie Hackett
Business Development Manager
bd@pharmnet-cro.com

www.pharmnet-cro.com
<https://www.linkedin.com/company/pharmnet/>



Gabriela Smaga
Business Development Representative
solutions@MONIPOL.com

www.MONIPOL.com
<https://www.linkedin.com/company/monipol/>